Lexicon Pharmaceuticals is gearing up to resubmit its New Drug Application (NDA) for sotagliflozin as a complement to insulin treatment for type 1 diabetes, in light of recent input from the FDA. This move follows a complete response letter (CRL) from the FDA regarding the initial NDA for sotagliflozin in 2019. The company is currently focused on incorporating the FDA’s suggestions and is committed to progressing with the resubmission procedure.
Lexicon Pharmaceuticals Inc. (LXRX) Shows Positive Momentum in Stock Performance on March 11, 2024
On March 11, 2024, Lexicon Pharmaceuticals Inc. (LXRX) showed positive momentum in its stock performance. LXRX was trading in the middle of its 52-week range and above its 200-day simple moving average, indicating stability and a potential upward trend.
The price of LXRX shares increased by $0.02, or 0.93%, since the previous trading day, closing at $2.17. In pre-market trading, the stock rose by $0.41.
Investors may be encouraged by the price momentum and potential growth in Lexicon Pharmaceuticals Inc. It is important to conduct research before making investment decisions, as market conditions can change rapidly. With LXRX’s positive performance on March 11, investors may want to monitor this stock for future opportunities.
Lexicon Pharmaceuticals, Inc. (LXRX) Reports Decrease in Total Revenue and Net Income in 2024
On March 11, 2024, Lexicon Pharmaceuticals, Inc. (LXRX) experienced a decrease in total revenue compared to the previous year and the last quarter. According to data from CNN Money, the total revenue for the company was $139.00K in the past year, which decreased by 53.36% from the previous year. In the third quarter of the fiscal year, the total revenue was $162.00K, showing a decrease of 48.9% from the previous quarter.
Similarly, the net income for Lexicon Pharmaceuticals, Inc. also saw a decrease in both the yearly and quarterly comparisons. The net income was reported as -$101.94M in the past year, which decreased by 16.16% from the previous year. In the third quarter, the net income was -$50.52M, showing a decrease of 12.52% from the previous quarter.
Despite the decreases in total revenue and net income, there was a slight increase in earnings per share (EPS) for Lexicon Pharmaceuticals, Inc. The EPS was reported as -$0.62 in the past year, which increased by 2.09% from the previous year. In the third quarter, the EPS was -$0.21, showing an increase of 5.93% from the previous quarter.
